<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>International Journal of Radiation Research</title>
<title_fa>نشریه پرتو پژوه</title_fa>
<short_title>Int J Radiat Res</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ijrr.com</web_url>
<journal_hbi_system_id>79</journal_hbi_system_id>
<journal_hbi_system_user>journal79</journal_hbi_system_user>
<journal_id_issn>2322-3243</journal_id_issn>
<journal_id_issn_online>2345-4229</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/ijrr</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1385</year>
	<month>12</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2007</year>
	<month>3</month>
	<day>1</day>
</pubdate>
<volume>4</volume>
<number>4</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Production and evaluation of [67Ga]-DTPA-Rituximab </title>
	<subject_fa>Radiation Biology</subject_fa>
	<subject>Radiation Biology</subject>
	<content_type_fa>تحقيق بديع</content_type_fa>
	<content_type>Original Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;span style=&quot;font-weight: bold&quot;&gt;
Background:&lt;/span&gt; In order to obtain an anti-CD20
conjugate to be used in future therapeutic studies with
therapeutic radioisotopes, 67Ga-labeled antibody was
prepared as a model of metal chelated
immunoconjugate for preliminary dosimetric and
biodistribution studies. &lt;span style=&quot;font-weight: bold&quot;&gt;Materials and Methods:&lt;/span&gt;
Rituximab was labeled with [67Ga]-gallium chloride
after residulation with freshly prepared cyclic DTPAdianhydride.
The best results of the conjugation were
obtained by the addition of 1 ml of a rituximab
pharmaceutical solution (5 mg/ml, in phosphate
buffer, pH=8) to a glass tube pre-coated with DTPAdianhydride
(0.01 mg) at 25|o|C with continuous mild
stirring for 30 min. The final isotonic 67Ga-DTPArituximab
complex was checked by gel electrophoresis
for radiolysis/chemolysis control. Radio-TLC was
performed to ensure the formation of only one
species. Preliminary in vivo studies in normal rat
model were performed to determine the
biodistribution of the radioimmunoconjugate up to 6
hours. &lt;span style=&quot;font-weight: bold&quot;&gt;Results:&lt;/span&gt; Radio-thin layer chromatography
showed an overall radiochemical purity of 96-99% at
optimized conditions (specific activity =300-500
MBq/mg, labeling efficiency 77%). Gel electrophoresis
showed no protein cleavage after radiolabeling.
&lt;span style=&quot;font-weight: bold&quot;&gt;Conclusion:&lt;/span&gt; Preliminary in vivo studies in normal rat
model showed [67Ga]-DTPA-rituximab is a good probe
for bio-dosimetry of therapeutic rituximab conjugates.
&lt;br&gt;Iran. J. Radiat. Res., 2007 4 (4): 187-193</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Gallium-67, rituximab, radiolabeling, biodistribution, cyclotron.</keyword>
	<start_page>187</start_page>
	<end_page>196</end_page>
	<web_url>http://ijrr.com/browse.php?a_code=A-10-1-222&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>A. R.</first_name>
	<middle_name></middle_name>
	<last_name>Jalilian</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>ajalilian@nrcam.org</email>
	<code>79003194753284600676</code>
	<orcid>79003194753284600676</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>L.</first_name>
	<middle_name></middle_name>
	<last_name>Mirsadegh</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>79003194753284600677</code>
	<orcid>79003194753284600677</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>R.</first_name>
	<middle_name></middle_name>
	<last_name>Haji-Hosseini</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>79003194753284600678</code>
	<orcid>79003194753284600678</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>S.</first_name>
	<middle_name></middle_name>
	<last_name>Rajabifar</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>79003194753284600679</code>
	<orcid>79003194753284600679</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>F.</first_name>
	<middle_name></middle_name>
	<last_name>Bolurinovin</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>79003194753284600680</code>
	<orcid>79003194753284600680</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
